Pharmaceuticals This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the most recent publications within this specialty of the MedWorm directory. This is page number 27.

A New Assessment Tool for Ataxia Syndromes: The "STAND" (Scale To Assess Ataxia and Neurologic Dysfunction) (PD2.001)
CONCLUSIONS: The STAND's quantification of non-ataxic neurologic symptoms should provide greater diagnostic and prognostic utility than scales that assess ataxic symptoms alone.Disclosure: Dr. Zesiewicz has received personal compensation for activities with Teva Neuroscience, GE, ProCE, and UCB Pharma as a speaker. Dr. Zesiewicz has received research support from Friedreich's Ataxia Research Alliance, Allon Pharmaceuticals, GlaxoSmithKline, Inc. and UCB Pharma. Dr. Zesiewicz has received research support from Friedreich's Ataxia Research Alliance. Dr. Shaw has nothing to disclose. Dr. Jahan has nothing to disclose. Dr. Sul...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Zesiewicz, T., Shaw, J., Jahan, I., Sullivan, K., Allison, K., Staffetti, J., Greenstein, P., Gooch, C., Vu, T. Tags: PD2 Movement Disorders: Ataxias Source Type: research

Comparison of Patients Treated with Natalizumab and Interferon-beta/Glatiramer Using Propensity-Matched Multiple Sclerosis Registry Data (P01.211)
CONCLUSIONS: Natalizumab treatment was associated with a significantly reduced risk of relapse compared with IFN and GA in a contemporaneously and propensity matched comparison of patients across 2 observational studies. While inferior to randomized clinical trials, the propensity score matching technique could be useful when head-to-head randomized trial evidence is lacking.Supported by: Biogen Idec Inc. and Elan Pharmaceuticals, Inc.Disclosure: Dr. Spelman hs received research support from Novartis. Dr. Pellegrini has received personal compensation for activities with Biogen Idec. Dr. Zhang has received personal compensa...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Spelman, T., Pellegrini, F., Zhang, A., Hyde, R., Pace, A., Belachew, S., Trojano, M., Wiendl, H., Kappos, L., Verheul, F., Grand-Maison, F., Izquierdo, G., Butzkueven, H., MSCOMET Investigators (an MSBase Substudy), , TOP Investigators, Tags: P01 Multiple Sclerosis: MS Treatments Source Type: research

Indirect Comparisons of Oral Fingolimod Versus Natalizumab on Measures of Disease Freedom Based on Results from FREEDOMS and AFFIRM (P01.209)
CONCLUSIONS: Results suggest that in an AFFIRM-like population, when differences between the FREEDOMS and AFFIRM trials in patient characteristics and endpoint definitions are taken into account, fingolimod may have an effect more similar to natalizumab with respect to probabilities of being free from relapses, disability progression and Gd T1 lesions than trial results suggest. However, this needs to be interpreted with caution, and cannot be compared to evidence from a randomized clinical trial.Supported by: Novartis Pharma AG, Basel, Switzerland.Disclosure: Dr. Nixon has received personal compensation for activities wit...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Nixon, R., Bergvall, N., Sfikas, N., Chin, P., Tomic, D., Cutter, G., Kappos, L. Tags: P01 Multiple Sclerosis: MS Treatments Source Type: research

Fingolimod Initiation at the Time of Return of Clinical Activity Following Natalizumab Cessation: Short Term Outcome (P01.208)
CONCLUSIONS: In our observations, fingolimod failed to control post NTZ cessation rebound of clinical activity despite drug induced lymphopenia. Regarding pharmokinetics data, earlier introduction of fingolimod (<3 months after NTZ interruption) may be more appropriate to control post natalizumab withdrawal relapses, but might be associated with maintenance of PML risk.Disclosure: Dr. Depaz has nothing to disclose. Dr. Gueguen has received personal compensation for activities with Teva Neuroscience and Novartis as a speaker. Dr. Gueguen has received personal compensation in an editorial capacity for Teva Neuroscience an...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Depaz, R., Gueguen, A., Deschamps, R., Mouligner, A., Bensa, C., Gout, O. Tags: P01 Multiple Sclerosis: MS Treatments Source Type: research

Efficacy of Fingolimod Treatment in Multiple Sclerosis Patients: A Multicenter Experience in Clinical Practice (P01.204)
CONCLUSIONS: In clinical practice, fingolimod is effective in reducing disease activity and progression of disability over the treatment period. The amount of efficacy was more pronounced than reported in the pivotal registration trials.Disclosure: Dr. Totaro has received personal compensation for activities with Bayer Pharmaceuticals Corporation, Biogen Idec, Merck-Serono, Sanofi-Aventis Pharmaceuticals, Inc., and Novartis as a speaker. Dr. Costantino has received personal compensation for activities with Bayer Pharma, Biogen Idec, Merck-Serono, Sanofi-Aventis Pharmaceuticals, Inc., and Novartis. Dr. Fantozzi has received...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Totaro, R., Costantino, G., Fantozzi, R., Bellantonio, P., Rossi, M., Di Carmine, C., Fuiani, A., Mundi, C., Ruggieri, S., Carolei, A. Tags: P01 Multiple Sclerosis: MS Treatments Source Type: research

Natalizumab Discontinuation after the 24th Course: Which Is Way? The TY-STOP Study (P01.197)
CONCLUSIONS: Our data show a protective effect of Natalizumab on MRI activity during the 12 months of follow-up. Considering the protective effect on MRI activity, Natalizumab should be continued over the 24 administrations according to the evaluation of patients' risk to develop PML.Disclosure: Dr. Clerico has nothing to disclose. Dr. De Mercanti has nothing to disclose. Dr. Piazza has nothing to disclose. Dr. Gned has nothing to disclose. Dr. Brescia Morra has nothing to disclose. Dr. Lanzillo has nothing to disclose. Dr. Amato has nothing to disclose. Dr. Quarantelli has nothing to disclose. Dr. Ghezzi has received pers...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Clerico, M., De Mercanti, S., Piazza, F., Gned, D., Brescia Morra, V., Lanzillo, R., Amato, L., Quarantelli, M., Ghezzi, A., Bianchi, A., Baroncini, D., Gibbin, M., Vargas, J., Salemi, G., Realmuto, S., Ferro, M. T., Vitetta, F., Sola, P., Paolicelli, D., Tags: P01 Multiple Sclerosis: MS Treatments Source Type: research

18-Month Interim Results of a Registry Study To Establish Long-Term Safety and Pharmaco-Economic Data on Fingolimod (Gilenya(R)) in Multiple Sclerosis Patients in Germany (PANGAEA) (P01.185)
CONCLUSIONS: First annual results are in accordance with the positive known profile of fingolimod. PANGAEA will continue to deliver transparent information for fingolimod under real-life conditions.Supported by: Novartis Pharma GmbH, Germany.Disclosure: Dr. Ziemssen has received personal compensation for activities with Almirall, Biogen Idec, Bayer Pharmaceuticals Corporation, Genzyme Corporation, GlaxoSmithKline, Merck Sharp & Dohme Limited, Merck Serono, Novartis, Sanofi-Aventis Pharmaceuticals, Inc., Teva Neuroscience, Synthon as a consultant. Dr. Ziemssen has received research support from Biogen Idec, Bayer Pharma...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Ziemssen, T., Diaz Lorente, M., Vollmar, P., Meergans, M., Tracik, F. M., Kempcke, R., van Lokven, T. Tags: P01 Multiple Sclerosis: Treatment Safety Source Type: research

Phase 2 BOLD Extension Study Safety Results for Siponimod (BAF312) in Patients with Relapsing-Remitting Multiple Sclerosis (P01.176)
CONCLUSIONS: Siponimod was well tolerated during the first 12 months of extension, in line with the core trial, and no new safety signals were observed.Supported by: Novartis Pharma AG.Disclosure: Dr. Hartung has received personal compensation for activities with Biogen Idec, Teva Neuroscience, Sanofi-Aventis Pharmaceuticals, Inc., Bayer, Novartis, and Merck Serono. Dr. Selmaj has received personal compensation for activities with Biogen Idec, Genzyme, Ono Pharmaceutical, Novartis, Bayer, Hoffmann LaRoche, Merck, Serono and Synthon. Dr. Li has received personal compensation for activities with Genzyme, Novartis, and Nuron ...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Hartung, H.-P., Selmaj, K., Li, D., Hemmer, B., Freedman, M., Stuve, O., Rieckmann, P., Montalban, X., Ziemssen, T., Zhang-Auberson, L., Hunter, B., Rochotte, E., Wallstrom, E., Kappos, L. Tags: P01 Multiple Sclerosis: Treatment Safety Source Type: research

Cancer Incidence in 677 Mitoxantrone-Treated People with Multiple Sclerosis: A Retrospective German Single Center Cohort Study (P01.175)
CONCLUSIONS: This data set indicates an acceptably low carcinogenic potential of mitoxantrone in MS patients at medium-term, which may help to inform treatment decisions.Disclosure: Dr. Buttmann has received personal compensation from Almirall Hermal GmbH for serving on an advisory board. Dr. Buttmann received research support from Merck Serono and Novartis Pharma. Dr. Seuffert has nothing to disclose. Dr. Maeder has nothing to disclose. Dr. Stoll has nothing to disclose. Dr. Toyka has received personal compensation for activities with pharmaceutical companies as an advisory board member, speaker, and consultant. Dr. Toyka...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Buttmann, M., Seuffert, L., Maeder, U., Stoll, G., Toyka, K. Tags: P01 Multiple Sclerosis: Treatment Safety Source Type: research

Adverse Event Profile of Alemtuzumab over Time in Active Relapsing-Remitting Multiple Sclerosis Patients Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.174)
CONCLUSIONS: The rate of AEs was similar across treatment arms except during the months with alemtuzumab administration where the excess was mostly attributable to IARs. The incidence of endocrine disorders was higher in the second year consistent with delayed onset.Supported by: Genzyme, a Sanofi company and Bayer Healthcare Pharmaceuticals.Disclosure: Dr. LaGanke has served as a consultant for Acorda Therapeutics, Bayer, Biogen Idec, Cephalon, EMD Serono, Genzyme, Novartis, Pfizer, Questcor, Strativa, Teva, and UCB. Dr. Arnold has received personal compensation or research support from Bayer Healthcare, Biogen Idec, Gene...
Source: Neurology - February 14, 2013 Category: Neurology Authors: LaGanke, C., Arnold, D., Cohen, J., Coles, A., Confavreux, C., Fox, E., Hartung, H., Havrdova, E., Selmaj, K., Weiner, H., Miller, T., Twyman, C., Lake, S., Margolin, D., Panzara, M., Compston, A. Tags: P01 Multiple Sclerosis: Treatment Safety Source Type: research

Detection, Incidence, and Management of Thyroid Autoimmunity in Comparison of Alemtuzumab and Rebif(R) in Multiple Sclerosis (CARE-MS) I and II (P01.173)
CONCLUSIONS: CARE-MS thyroid disorders occurred in a similar proportion of patients as in CAMMS223. The safety monitoring program in place allowed for early detection and effective management. These disorders tend to be delayed in nature so incidence is expected to rise with continued follow-up.Supported by: Genzyme, a Sanofi company and Bayer Healthcare Pharmaceuticals.Disclosure: Dr. Miller has received personal compensation for activities with Allergan, Bayer, Biogen Idec, Eli Lilly, EMD Serono, Forest, Novartis, Sanofi Aventis, and Teva as a speaker. Dr. Miller has received research support from Allergan, Biogen Idec, ...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Miller, T., Arnold, D., Cohen, J., Coles, A., Confavreux, C., Fox, E., Hartung, H., Havrdova, E., Selmaj, K., Weiner, H., Lake, S., Margolin, D., Oyuela, P., Panzara, M., Compston, A. Tags: P01 Multiple Sclerosis: Treatment Safety Source Type: research

Comparison of Infection Risk with Alemtuzumab and SC IFNB-1a in Patients with Multiple Sclerosis Who Experienced Disease Activity While on Prior Therapy (CARE-MS II) (P01.172)
CONCLUSIONS: Although alemtuzumab increased the risk for infection compared with IFNB-1a in CARE-MS II, all infections were manageable, few were serious, and none led to study discontinuation.Supported by: Genzyme, a Sanofi company and Bayer Healthcare Pharmaceuticals.Disclosure: Dr. Wray has received personal compensation for activities with Serono, Inc., Bayer Pharmaceuticals Corporation, Genzyme Corporation, Biogen Idec, Novartis and Teva Neuroscience as a consultant, speaker and/or serving on an advisory board. Dr. Wray has received research support from Accorda, Biogen Idec, Elan, Genzyme, Novartis, Ono, Roche and Ser...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Wray, S., Arnold, D., Cohen, J., Coles, A., Confavreux, C., Fox, E., Hartung, H., Havrdova, E., Selmaj, K., Weiner, H., Miller, T., Twyman, C., Lake, S., Margolin, D., Panzara, M., Compston, A. Tags: P01 Multiple Sclerosis: Treatment Safety Source Type: research

Frequency of Infections during Treatment with Teriflunomide: Pooled Data from Three Placebo-Controlled Teriflunomide Studies (P01.171)
CONCLUSIONS: Teriflunomide had a low incidence of serious infections, which was not different from placebo. Mean reductions in WBC counts were small in magnitude, often stabilized during treatment, and were not associated with infections. These findings provide evidence that risk of infection is not increased by teriflunomide treatment.Supported by: Genzyme, a Sanofi company.Disclosure: Dr. Singer has received personal compensation for activities with Acorda, Bayer, Biogen Idec, EMD Serono, Genentech, Genzyme, Novartis, Pfizer and Teva as a speaker or consultant. Dr. Singer has received research support from Biogen-Idec, G...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Singer, B., Comi, G., Miller, A., Olsson, T., Wolinsky, J., Kappos, L., Confavreux, C., Freedman, M., Benzerdjeb, H., Li, H., Truffinet, P., O'Connor, P. Tags: P01 Multiple Sclerosis: Treatment Safety Source Type: research

Immune Response to Seasonal Influenza Vaccination in Patients with Relapsing Multiple Sclerosis Treated with Teriflunomide: The TERIVA Study (P01.169)
CONCLUSIONS: Teriflunomide-treated patients mount effective immune responses to seasonal influenza vaccination, suggesting teriflunomide does not significantly affect memory responses to influenza vaccine.Supported by: Genzyme, a Sanofi company.Disclosure: Dr. O'Connor has received personal compensation for activities with Biogen Idec, EMD Serono, Novartis, Roche, Genzyme Corporation, and Teva Neuroscience. Dr. O'Conner has received research support from Biogen Idec, Novartis, Roche, Genzyme Corporation, and Teva Neuroscience. Dr. Bar-Or has received personal compensation for activities with Amplimmune, Aventis Pharmaceuti...
Source: Neurology - February 14, 2013 Category: Neurology Authors: O'Connor, P., Bar-Or, A., Freedman, M., Kremenchutzky, M., Menguy-Vacheron, F., Bauer, D., Truffinet, P., Benamor, M. Tags: P01 Multiple Sclerosis: Treatment Safety Source Type: research

Long-Term Safety of Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from Phase 3 FREEDOMS II Extension Study (P01.165)
CONCLUSIONS: The long-term safety results of FREEDOMS II extension study were generally consistent with previous fingolimod studies. Switching therapy from placebo to fingolimod after 24 months identified no unexpected safety concerns.Supported by: Novartis Pharma AG, Basel, Switzerland.Disclosure: Dr. Vollmer has received personal compensation for activities with Genzyme Corporation, Acorda Therapeutics, Accelerated Cure Projects for MS, Bristol-Myers Squibb Company, Teva Neuroscience, Biogen Idec, Novartis, and Hoffman-LaRoche. Dr. Vollmer has received research support from Teva Neuroscience, Genzyme Corporation, Ono Pha...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Vollmer, T., Jeffery, D., Goodin, D., Kappos, L., Lublin, F., Radue, E.-W., Rammohan, K., Reder, A., Agius, M., Stites, T., Li, B., Cappiello, L., von Rosenstiel, P., Calabresi, P. Tags: P01 Multiple Sclerosis: Treatment Safety Source Type: research

Gastrointestinal Tolerability Events in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated with Oral BG-12 (Dimethyl Fumarate) in DEFINE and CONFIRM (P01.164)
CONCLUSIONS: The incidence of GI AEs was highest in the first 3 months of treatment (most commonly abdominal/upper abdominal pain and nausea/vomiting, and diarrhea). Most events were mild-to-moderate in severity and resolved within the first 3 months while few GI events resulted in treatment discontinuation. Further studies are needed to evaluate the efficacy of individual management strategies.Supported by: Biogen Idec Inc.Disclosure: Dr. Selmaj has received personal compensation for activities with Biogen Idec, Genzyme, Ono Pharmaceutical, Novartis, Bayer, Hoffmann LaRoche, Merck, Serono and Synthon. Dr. Gold has receive...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Meltzer, L., Selmaj, K., Gold, R., Fox, R., Havrdova, E., Giovannoni, G., Pace, A., Novas, M., Hotermans, C., Dawson, K., Phillips, J. T. Tags: P01 Multiple Sclerosis: Treatment Safety Source Type: research

Assessment of Potential Risk of Progressive Multifocal Leukoencephalopathy with Fingolimod Compared with That of Natalizumab (P01.160)
CONCLUSIONS: As of Sep 2012, the absence of PML cases associated with fingolimod yields point estimates that indicate that the potential risk with fingolimod is lower than for natalizumab.Supported by: Novartis Pharma AG, Basel, Switzerland.Disclosure: Dr. Francis has received personal compensation for activities with Novartis as an employee. Dr. Francis hold stock and/or stock options in Novartis. Dr. Dahlke has received personal compensation for activities with Novartis. Dr. Von Rosenstiel has received personal compensation for activities with Novartis. Dr. Sfikas has received personal compensation for activities with No...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Francis, G., Dahlke, F., von Rosenstiel, P., Sfikas, N. Tags: P01 Multiple Sclerosis: Treatment Safety Source Type: research

Long-Term Efficacy, Safety and Tolerability of Ponesimod in Patients with Relapsing-Remitting Multiple Sclerosis (P01.156)
CONCLUSIONS: Long-term treatment with ponesimod maintained efficacy on clinical and MRI outcomes; efficacy on both measures was re-affirmed in ex-placebo patients. No new safety findings were identified.Supported by: Actelion Pharmaceuticals Ltd.Disclosure: Dr. Freedman has received personal compensation for activities with Bayer, Biogen Idec, Teva, Merck Serono, Novartis, Sanofi, and Celgene. Dr. Freedman's institution has received research support from Bayer Healthcare and Genzyme. Dr. Boster has received personal compensation from Merck Serono, Biogen, Novartis, Sun-Pharma, Roche, Genetech, National MS Society, NIH, and...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Freedman, M., Boster, A., Fernandez, O., Melanson, M., Pozzilli, C., D'Ambrosio, D., Sidorenko, T., Olsson, T. Tags: P01 Multiple Sclerosis: Treatment Safety Source Type: research

ANNA-2 Autoantibody Syndrome Associated with Remote Cervical Carcinoma and Good Response to Immunomodulatory Therapy (P01.110)
CONCLUSIONS: We present a rare patient in whom a clinical condition characterized by encephalopathy, diffuse myoclonus, ataxia and leg rigidity associated with high ANNA-2 titers developed 15 years after hysterectomy for cervical cancer. Extensive work up over 5 years showed no evidence for additional neoplasm. Aggressive medical treatment resulted in marked improvement of symptoms.Disclosure: Dr. Machado has nothing to disclose. Dr. Sorokin has nothing to disclose. Dr. Jabbari has received research support from Allergan, Inc., Merz Pharma, and Ipsen.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Machado, D., Sorokin, A., Jabbari, B. Tags: P01 Neuro-oncology: Other I Source Type: research

Clinical Spectrum and Course in Individuals with Intravascular Large B-Cell Lymphoma Affecting the Nervous System: A Case Series (P01.102)
CONCLUSIONS: Although IVLBL has distinct pathological features, its clinical presentation can be protean, ranging from mild myopathy to fulminant brain or multi-organ failure. The patient's optimal chance for survival relies on early pathological diagnosis and prompt, aggressive chemotherapy.Disclosure: Dr. Zhong has nothing to disclose. Dr. Oakes has nothing to disclose. Dr. Sonnen has nothing to disclose. Dr. Ransom has nothing to disclose. Dr. Longstreth has nothing to disclose. Dr. Mrugala has received personal compensation for activities with UCB Pharma, Sigma-Tau Pharmaceuticals, and Perceptive Informatics. Dr. Mruga...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Zhong, N., Oakes, P., Sonnen, J., Ransom, B., Longstreth, W. T., Mrugala, M. Tags: P01 Neuro-Oncology: Therapeutics Source Type: research

Effect of Valproic Acid on Seizure Control and on Survival in Patients with Glioblastoma Multiforme (P01.096)
CONCLUSIONS: Polytherapy with VPA and LEV strongly contributes to seizure control to either of these as monotherapy. Use of VPA together with chemoradiation by temozolomide results in a 2 months longer survival of patients with GBM.Disclosure: Dr. Kerkhof has nothing to disclose. Dr. Dielemans has nothing to disclose. Dr. van Breemen has nothing to disclose. Dr. Zwinkels has nothing to disclose. Dr. Walchenbach has nothing to disclose. Dr. Taphoorn has nothing to disclose. Dr. Vecht has received research support from UCB Pharma.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Kerkhof, M., Dielemans, J., van Breemen, M., Zwinkels, H., Walchenbach, R., Taphoorn, M., Vecht, C. Tags: P01 Neuro-Oncology: Therapeutics Source Type: research

Evaluation of the Frequency and the Association of Female Pelvic/Genital Pain and Chronic Headache (P01.081)
CONCLUSIONS: It is important to ask women with chronic headache about sexual pain and, if present, be able to offer a management option.Supported by: In part, by an unrestricted grant from Merck.Disclosure: Dr. Gordon has received personal compensation for activities with Purdue Pharma, Pfizer, Eli Lilly, Jansen Ortho and Allergan. Dr. Lay has received personal compensation for activities with Ortho-McNeil Pharmaceuticals, Merck, and Allergan.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Gordon, A., Lay, C. Tags: P01 Headache: Clinical Presentation and Therapeutics Source Type: research

Non-Interventional Study of the Switch from Oral Treatment to Rotigotine Transdermal System in Patients with Parkinson's Disease and Gastrointestinal Symptoms (P01.067)
CONCLUSIONS: This study suggests that a switch from oral PD medication to transdermal dopaminergic therapy (rotigotine) may improve pre-existing GI symptoms among patients with PD. Further studies are needed to confirm this finding. An ongoing double-blind trial investigating the effects of rotigotine transdermal system on GI motility will investigate this further.Supported by: UCB Pharma, Monheim am Rhein, Germany.Disclosure: Dr. Woitalla has received personal compensation for activities with UCB Pharma, GlaxoSmithKline, Inc. and Orion Pharma as a consultant. Dr. Lauterbach is an employee of UCB Pharma. Dr. Berkels has re...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Woitalla, D., Lauterbach, T., Berkels, R., Grieger, F., Timmermann, L., Kassubek, J. Tags: P01 Movement Disorders: Parkinson ' s Disease Therapy Source Type: research

Efficacy of Tolcapon on Parkinson's Disease Associated Non Motor Symptoms: The TANIMOS Study (P01.066)
CONCLUSIONS: This is the first trial that demonstrates the efficacy of tolcapone addition on the appearance of non motor symptoms in PD patients by neurologists, the patients themselves and their caregivers.Supported by: MEDA Pharma.Disclosure: Dr. Muller has received personal compensation for activities with GlaxoSmithKline, Inc., Archimedes, Meda, Merck Serono, Orion, Abbott, and Novartis. Dr. Muller has received research support from Merck Serono and Orion. Dr. Witzer has received personal compensation for activities with MEDA Pharma as an employee. TANIMOS Study Group members have received personal compensation for act...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Muller, T., Witzer, M., TANIMOS Study Group, Tags: P01 Movement Disorders: Parkinson ' s Disease Therapy Source Type: research

Long-Term Safety of IPX066 Extended-Release Carbidopa-Levodopa Capsules in Patients with Motor Fluctuations in Advanced Parkinson's Disease (P01.065)
CONCLUSIONS: Overall, IPX066 demonstrated a favorable tolerability profile during long-term management of advanced PD. Throughout open-label treatment, the percentage of patients reporting AEs was comparable to those in the original IPX066 trials.Supported by: Impax Pharmaceuticals.Disclosure: Dr. Ellenbogen has received personal compensation for activities with XenoPort, Inc., Teva Neuroscience, Boehringer Ingelheim Pharmaceuticals, Inc., Allergan, Inc., Novartis, GlaxoSmithKline, Inc. and Ipsen. Dr. Nausieda has received personal compensation for activities with Impax, Novartis, UCB Pharma, and Teva Neuroscience. Dr. Nau...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Ellenbogen, A., Nausieda, P., Pourcher, E., Rudzinska, M., Kell, S., O'Connell, M., Hsu, A., Gupta, S. Tags: P01 Movement Disorders: Parkinson ' s Disease Therapy Source Type: research

Long-Term Safety of IPX066 Extended-Release Carbidopa-Levodopa Capsules in Patients with Early Parkinson's Disease (P01.064)
CONCLUSIONS: Overall, IPX066 demonstrated a favorable tolerability profile throughout extended dosing in early PD. During open-label administration, the frequency of AEs reported was typical of this population.Supported by: Impax Pharmaceuticals.Disclosure: Dr. Nausieda has received personal compensation for activities with Impax, Novartis, UCB Pharma, and Teva Neuroscience. Dr. Nausieda holds stock and/or stock options in Teva Neuroscience, Phytopharm PLC, and Impax, which sponsored research in which Dr. Nausieda was involved as an investigator. Dr. Nausieda holds stock and/or stock options in Abbott, Bristol-Myers Squibb...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Nausieda, P., Rudzinska, M., Kell, S., O'Connell, M., Hsu, A., Gupta, S. Tags: P01 Movement Disorders: Parkinson ' s Disease Therapy Source Type: research

Safinamide Add on to L-Dopa: A Randomized, Placebo-Controlled, 24-Week Global Trial in Patients with Parkinson's Disease (PD) and Motor Fluctuations (SETTLE) (P01.062)
CONCLUSIONS: Safinamide 50-100 mg/day met the primary efficacy objective of significantly improving ON time without any increase in troublesome dyskinesia, and there was improvement in multiple secondary efficacy measures. These results confirm the efficacy and good tolerability demonstrated previously in Study 016 at daily doses of 50mg and 100 mg.Supported by: Newron/Merck Serono.Disclosure: Dr. Schapira has received personal compensation for activities with GSK, Orion-Novartis, Teva-Lundbeck, Serono, BI as a consultant. Dr. Schapira has received personal compensation in an editorial capacity for European Journal of Neur...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Schapira, A., Fox, S., Hauser, R., Jankovic, J., Jost, W., Kulisevsky, J., Pahwa, R., Poewe, W., Anand, R. Tags: P01 Movement Disorders: Parkinson ' s Disease Therapy Source Type: research

Safinamide as an Add-On Therapy to a Stable Dose of a Single Dopamine Agonist: Results from a Randomized, Placebo-Controlled, 24-Week Multicenter Trial in Early Idiopathic Parkinson Disease (PD) Patients (MOTION Study) (P01.061)
CONCLUSIONS: Safinamide 100mg/day met the primary objective of significantly improving motor symptoms, quality of life, and borderline significantly ADL, compared to placebo as add-on to a single DA-agonist. These results confirm the efficacy and good tolerability profile of safinamide, already demonstrated in previous studies. Safinamide is a new treatment option for patients with early PD who show signs of loss of benefit on DA-agonist monotherapy.Supported by: Newron/MerckSerono.Disclosure: Dr. Barone has received personal compensation for activities with Boehringer Ingelheim Pharmaceuticals, Inc., Eisai Inc., GE Health...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Barone, P., Fernandez, H., Ferreira, J., Mueller, T., Saint- Hilaire, M., Stacy, M., Tolosa, E., Anand, R. Tags: P01 Movement Disorders: Parkinson ' s Disease Therapy Source Type: research

Interim Results from an International, Open-Label Study of Levodopa-Carbidopa Intestinal Gel in Patients with Advanced Parkinson's Disease: Efficacy Analyses by Subgroups (P01.060)
CONCLUSIONS: LCIG produced significant and consistent improvements in motor function in advanced PD patients experiencing motor fluctuations. Supported by: Abbott. Abbott participated in the study design, research, data collection, analysis and interpretation of data, writing, reviewing, and approving the publication. Nathan Rustay, of Abbott, provided medical writing assistance in the development of this publication.Disclosure: Dr. Odin has received personal compensation for activities with Abbott. Dr. Odin has received research support from Abbott. Dr. Espay has received personal compensation for activities with Solvay, ...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Odin, P., Espay, A., Vanagunas, A., Hauser, R., Fernandez, H., Standaert, D., Robieson, W., Pritchett, Y., Widnell, K., Chatamra, K., Benesh, J., Lenz, R. Tags: P01 Movement Disorders: Parkinson ' s Disease Therapy Source Type: research

Sustained and Prolonged Striatal Dopamine Levels in Parkinson's Patients Following Enteral L-Dopa Gel Infusion: An In Vivo 11C-Raclopride PET Study (P01.059)
CONCLUSIONS: Enteral L-dopa gel infusions can generate a stable and prolonged dopamine delivery in advanced PD patients and improve quality of life, and motor and non-motor symptoms.Disclosure: Dr. Politis has nothing to disclose. Dr. Loane has nothing to disclose. Dr. Pavese has nothing to disclose. Dr. Brooks has received personal compensation for activities with General Electric, Neurology, AstraZeneca Pharmaceuticals, Lundbeck, Schering-Plough Corporation, Elan Corporation, and UCB Pharma. Dr. Chaudhuri has received personal compensation for activities with Solvay, UCB Pharma, GlaxoSmithKline, Inc., Ipsen, Britannia, a...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Politis, M., Loane, C., Pavese, N., Brooks, D., Chaudhuri, K., Piccini, P. Tags: P01 Movement Disorders: Parkinson ' s Disease Therapy Source Type: research

Good Outcomes Possible after a Prolonged Course of Refractory Status Epilepticus (P01.048)
CONCLUSIONS: There are reports of patients surviving prolonged treatment of refractory SE but typically outcomes are poor. Determining the prognosis for functional recovery and deciding on adequate treatment duration can be difficult in cases of refractory SE. This case illustrates treatment strategies that resulted in a good functional recovery even after months of refractory SE.Disclosure: Dr. Standley has nothing to disclose. Dr. Benbadis has received personal compensation for activities with Cyberonics, Inc., GlaxoSmithKline, Inc., Lundbeck, Sleemed/DigiTrace, UCB Pharma, and XLTEK. Dr. Benbadis has received personal c...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Standley, K., Benbadis, S. Tags: P01 Epilepsy: Therapeutics Source Type: research

Use of Rescue Medications by Lennox-Gastaut (LGS) Patients Treated with Clobazam during the CONTAIN Trial (P01.046)
CONCLUSIONS: Rescue medications were used infrequently during the maintenance period of CONTAIN. There were no clinically important or statistically significant differences between treatment groups in the percentage of patients who employed rescue medications on multiple occasions. However, there was a trend toward less frequent use of rescue medications in the low-, medium- and high-dosage clobazam groups.Supported by: Lundbeck LLC.Disclosure: Dr. Rosenfeld has received research support from Pfizer Inc, UCB Pharma, Eisai, Inc., Valeant Pharmaceuticals, Medtronic, Inc., Lundbeck, Sunovion, Artemis, SK Life, Upsher Smith. D...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Rosenfeld, W., Lee, D., Isojarvi, J. Tags: P01 Epilepsy: Therapeutics Source Type: research

Simultaneous Improvement of Tics and Dug-Induced Parkinsonism after Gpi DBS: A Case Report (P01.038)
CONCLUSIONS: Severe DIP in this patient may be secondary to rapid re-titration of anti-dopaminerigic medications. Furthermore, since TS and DIP have differing pathophysiology, this case report supports theories that DBS "normalizes" basal ganglia circuitry and can therefore treat both hyperkinetic and hypokinetic disorders occurring simultaneously.Disclosure: Dr. Patel has nothing to disclose. Dr. Jimenez-Shahed has received personal compensation for activities with Teva Neuroscience, Allergan, Inc, Merz Pharma, Medtronic, Inc., and Lundbeck.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Patel, N., Jimenez Shahed, J. Tags: P01 Clinical Neurophysiology: Therapeutics Source Type: research

Significant Improvements on Muscle Performance and Walking Capacity after Progressive Resistance Training (PoRT) and Core and Stability Training (CoaST) for People with MS (P01.036)
CONCLUSIONS: Progressive resistance training (PoRT) and core and stability training (CoaST) in groups could improve muscle performance and walking distance for people in MS. Both physical interventions indicate to improve independence in daily life.Supported by: Novartis Pharma GmbH, Germany.Disclosure: Dr. Jolk has received personal compensation for activities with Novartis as a consultant. Dr. Artiguenave has nothing to disclose. Dr. Bernhardt has received personal compensation for activities with Bayer, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis Pharmaceuticals, Inc., and Teva Neuroscience. Dr. Bernhardt has re...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Jolk, C., Alcantara, R., Bernhardt, L., Marziniak, M., Platen, P. Tags: P01 Clinical Neurophysiology: Therapeutics Source Type: research

Peripheral Nerve Safety Measures in a Multicenter, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Study of Fulranumab in Patients with Painful Diabetic Neuropathy (P01.035)
CONCLUSIONS: There is no evidence that, at the doses and for the period studied, fulranumab was associated with an induced decrement in nerve function. An adequately powered and longer duration study is required to confirm these observations.Supported by: Janssen Research & Development, LLC (previously known as Johnson & Johnson Pharmaceutical Research & Development, L.L.C), New Jersey, USA.Disclosure: Dr. Polydefkis has received personal compensation for activities with Johnson & Johnson and Biogen Idec. Dr. Wang has received personal compensation for activities with Janssen Pharmaceutical as an employee. ...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Polydefkis, M., Wang, H., Romano, G., Frustaci, M. E., Cornblath, D., Thipphawong, J., Kelly, K., Arezzo, J. Tags: P01 Clinical Neurophysiology: Therapeutics Source Type: research

Awareness of Drug-Drug Interactions between Synthetic Hormones and Anti-Epileptic Medications: A Survey of Neurology, Obstetrics and Gynecology, Internal Medicine, and Psychiatry Residents (P01.034)
CONCLUSIONS: Awareness regarding important interactions between AEDs and hormonal contraception is low in all specialties. As these medications continue to be prescribed for conditions other than epilepsy, it is vital that physicians become aware of these interactions in order to provide optimal care to women of childbearing age. Further education through the development of guidelines and interactive educational materials is important and recommended during residency training.Disclosure: Dr. Sahay has nothing to disclose. Dr. Garic has nothing to disclose. Dr. Gawron has nothing to disclose. Dr. Hammond has nothing to disc...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Sahay, M., Garic, I., Gawron, L., Hammond, C., Kennedy, J., Macken, M., Schuele, S., Stika, C., York, S., Gerard, E. Tags: P01 Clinical Neurophysiology: Therapeutics Source Type: research

Initial Findings of a Randomized Double-Blinded Placebo-Controlled Study of Intravenous Immunoglobulin in Mild Cognitive Impairment Due to Alzheimer Disease (P01.013)
CONCLUSIONS: IVIG in subjects with MCI was associated with decreased brain atrophy and improvement of cognitive function on CDR-SB. Affect on conversion rate to AD is yet to be determined. These preliminarily positive but non-statistically significant results indicate that a relatively short course of IVIG in MCI may have disease-modulating effects in AD.Supported by: Sutter Institute for Medical Research; Octapharma.Disclosure: Dr. Kile's institution has received research support from Octapharma. Dr. Au has received research support from Octapharma. Dr. Parise's institution received personal compensation for activities wi...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Kile, S., Au, W., Parise, C., Low, R. Tags: P01 Aging and Dementia: Therapeutics and Clinical Trials Source Type: research

Abnormal Tactile Pressure Perception in Parkinson's Disease: A Perceptual Grasp (P01.010)
CONCLUSIONS: These results demonstrate that patients with PD have a perceptual grasp for the pressure exerted by tactile stimuli. This perceptual grasp may be a disorder of disengagement induced by frontal-executive dysfunction that is often associated with PD.Supported by: In part by the AAN 2012 Medical Student Summer Research Scholarship.Disclosure: Dr. Kesayan has nothing to disclose. Dr. Williamson has nothing to disclose. Dr. Falchook has received personal compensation for activities with the University of Florida College of Medicine, the Institute for Advancement of Human Behavior, and PeerView Institute. Dr. Okun h...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Kesayan, T., Williamson, J., Falchook, A., Okun, M., Malaty, I., Rodriguez, R., White, K., Hauser, R., Heilman, K. Tags: P01 Behavioral Neurology: Attention and Executive Functions Source Type: research

Effects of 5mg and 10mg Dalfampridine Extended Release Tablets on 6-Minute Walk Distance in People with Multiple Sclerosis: A Subgroup Analysis of a Double-Blind, Placebo-Controlled Trial (S01.007)
CONCLUSIONS: In these subjects with MS, twice daily dalfampridine-ER 10mg but not 5mg significantly improved 6MW distance relative to placebo.Supported by: Acorda Therapeutics, Inc.Disclosure: Dr. Applebee has nothing to disclose. Dr. Goodman has received personal compensation for activities with Acorda Therapeutics, Avanir, Biomarin, Biogen Idec, EMD Serono, Genzyme, Novartis, Pfizer, and Teva as a consultant. Dr. Goodman has received research support from Acorda Therapeutics, Biogen Idec, EMD Serono, Genzyme, Novartis, Ono, and Teva. Dr. Mayadev has nothing to disclose. Dr. Bethoux has received personal compensation for ...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Applebee, A., Goodman, A., Mayadev, A., Bethoux, F., Goldman, M., Klingler, M., Henney, H., Blight, A., Carrazana, E. Tags: S01 Multiple Sclerosis: Clinical Trials I Source Type: research

Patient Demographics and Health Plan Paid Costs in CIDP (PD1.007)
CONCLUSIONS: Annual health care costs for CIDP are substantial with a large cost burden in pharmacy utilization. IVIg (FDA approved for CIDP) is the primary cost driver. With the emphasis on the rational use of health care resources, studies are needed to determine optimal long-term treatment strategies for CIDP, particularly with regard to IVIg.Supported by: An American Brain Foundation - Myasthenia Gravis Foundation of America Clinician Scientist Development Award (Dr. Guptill).Disclosure: Dr. Guptill has received personal compensation for activities with UCB Pharma as a consultant. Dr. Bromberg has received personal com...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Guptill, J., Bromberg, M., Zhu, L., Sharma, B., Thompson, A., Krueger, A., Sanders, D. Tags: PD1 Peripheral Nerve Source Type: research

Teriflunomide Efficacy and Safety in Patients with Relapsing Multiple Sclerosis: Results from TOWER, a Second, Pivotal, Phase 3 Placebo-Controlled Study (S01.004)
CONCLUSIONS: Teriflunomide 14mg significantly reduced ARR and 12-week disability progression compared with placebo; 7mg significantly reduced ARR. Teriflunomide has a well-characterized safety profile. These results confirm those of TEMSO and support teriflunomide as a treatment option for patients with RMS.Supported by: Genzyme, a Sanofi company.Disclosure: Dr. Miller has received personal compensation for activities with Acorda Therapeutics, Biogen Idec, GlaxoSmithKline, Merck Serono, Novartis, Nuron Biotech, ONO, Genzyme/Sanofi, Questcor, Teva Neuroscience, and Accordant Health Services. Dr. Miller has received personal...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Miller, A., Kappos, L., Comi, G., Confavreux, C., Freedman, M., Olsson, T., Wolinsky, J., Bagulho, T., Delhay, J.-L., Zheng, Y., Truffinet, P., O'Connor, P. Tags: S01 Multiple Sclerosis: Clinical Trials I Source Type: research

Clinicopathologic Correlations in 172 Cases of REM Sleep Behavior Disorder {+/-} a Coexisting Neurologic Disorder (PL01.003)
CONCLUSIONS: In this large series of PSG-confirmed and probable RBD cases that underwent autopsy, the strong association of RBD with the synucleinopathies was further substantiated, and a wider spectrum of disorders that can underlie RBD is more apparent.Supported by: NIH grants AG015866, AG006786, AG016574, NS072187, NS072187-01S2, NS072026, AG19610; the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson's Disease Consortium); the Mangurian Foundation; National Parkinson Fou...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Boeve, B., Silber, M., Ferman, T., Lin, S.-C., Benarroch, E., Schmeichel, A., Ahlskog, J., Caselli, R., Jacobson, S., Sabbagh, M., Adler, C., Woodruff, B., Beach, T., Iranzo, A., Gelpi, E., Santamaria, J., Tolosa, E., Singer, C., Mash, D., Luca, C., Arnul Tags: PL01 Contemporary Clinical Issues Plenary Session Source Type: research

Radiologically Isolated Syndrome (RIS): 5-Year Risk for an Initial Clinical Event from a Multinational Cohort (PL01.002)
CONCLUSIONS: These data provide supportive evidence that risk of progression is predicated on the presence of established parameters in MS. Future directions involve worldwide, standardized efforts to capture prospective clinical and radiological data and strategies to prevent clinical onset.Supported by: On behalf of the Radiologically Isolated Syndrome Consortium (RISC) and Club Francophone de la SEP.Disclosure: Dr. Okuda has received personal compensation for activities with Acorda Therapeutics, Biogen Idec, Genzyme Corporation, Ipsen, and Teva Neuroscience. Dr. Siva has received personal compensation for consulting and...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Okuda, D., Siva, A., Kantarci, O., Inglese, M., Katz, I., Tutuncu, M., Keegan, M., Amato, M. P., De Stefano, N., Sormani, M. P., Pelletier, D., Lebrun Frenay, C. Tags: PL01 Contemporary Clinical Issues Plenary Session Source Type: research

The Safety and Efficacy of Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis in the SELECTION Extension Study: Primary Results (S01.001)
CONCLUSIONS: The efficacy of DAC HYP was sustained through the second year of therapy and the safety profile was similar in years 1 and 2. There was no evidence of rebound disease activity after washout.Supported by: Biogen Idec and Abbott Biotherapeutics.Disclosure: Dr. Giovannoni has received personal compensation for activities with Merck Serono, Biogen Idec, Vertex Pharmaceuticals, Bayer Schering Pharma, Pfizer Inc, Teva Pharmaceutical Industries Ltd, and Sanofi. Dr. Giovannoni has received research support from Biogen Idec, Merck Serono, Novartis, and Ironwood. Dr. Gold has received personal compensation for activitie...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Giovannoni, G., Gold, R., Selmaj, K., Havrdova, E., Montalban, X., Radue, E.-W., Stefoski, D., McNeill, M., Rana, J., Elkins, J., O'Neill, G. Tags: S01 Multiple Sclerosis: Clinical Trials I Source Type: research

Neuroimaging Somatosensory Perception and Extinction (P01.001)
CONCLUSIONS: The findings suggest that perception of lateralized somatosensory stimuli depends on a specific contralateral corticothalamic network (detailed above), and that failure of perception is associated with greater ipsilateral activation in homogolous regions.Supported by: Emory University.Disclosure: Dr. Meador has received research support from Pfizer and UCB Pharma. Dr. Revill has nothing to disclose. Dr. Epstein has nothing to disclose. Dr. Sathian has nothing to disclose. Dr. Loring has received research grant support from UCB, and Pfizer. Dr. Rorden has nothing to disclose.
Source: Neurology - February 14, 2013 Category: Neurology Authors: Meador, K., Revill, K., Epstein, C., Sathian, K., Loring, D., Rorden, C. Tags: P01 Behavioral Neurology: Attention and Executive Functions Source Type: research

No difference in overall survival reported in phase III TIVO-1 study of tivozanib vs. sorafenib for advanced renal cell carcinoma
Source: BioSpace Area: News AVEO Oncology and Astellas Pharma Inc. have announced overall survival (OS) data (secondary endpoint) for tivozanib, an oral, once-daily, investigational tyrosine kinase inhibitor, from the phase III TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) study in patients with advanced renal cell carcinoma (RCC). The final analysis shows a median OS of 28.8 months (95% CI: 22.5-NA) for tivozanib vs. 29.3 months (29.3 to NA) for the comparator arm, sorafenib. No statistical difference between the two arms (hazard ratio 1.245, p=0.105) was observed. TIVO-1 is a global, randomise...
Source: NeLM - News - February 14, 2013 Category: Drugs & Pharmacology Source Type: news

SERTRALINE HYDROCHLORIDEsolution, Concentrate [Aurobindo Pharma Limited]
Updated Date: Feb 14, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 14, 2013 Category: Drugs & Pharmacology Source Type: news

SULFAMETHOXAZOLE AND TRIMETHOPRIMsuspension [STI Pharma LLC]
Updated Date: Feb 14, 2013 EST
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - February 14, 2013 Category: Drugs & Pharmacology Source Type: news

Love in the Time of Neuroscience
"How on earth are you ever going to explain in terms of chemistry and physics so important a biological phenomenon as first love?"
Source: Forbes.com Healthcare News - February 13, 2013 Category: Pharmaceuticals Authors: David DiSalvo Source Type: news

Hawaii to launch new anti-obesity campaign for teens
Hawaii Gov. Neil Abercrombie and state Health Director Loretta Fuddy plan to unveil a new obesity prevention campaign for teenagers Thursday afternoon in the Hawaii Capitol auditorium. Island Pacific Academy students who helped with the advertising concepts for the campaign will watch the final versions of the ads for the first time, Abercrombie’s office said in a statement. The campaign is part of a plan to reverse the increasing obesity rates among Hawaii teens. The screening is also expected…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 13, 2013 Category: Pharmaceuticals Source Type: research